Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Monday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX opened at $0.95 on Monday. The business has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $1.75. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The company has a market capitalization of $55.89 million, a PE ratio of -0.40 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.